scholarly journals Myeloproliferative diseases as causative agents of portal and hepatic veins thrombosis

2007 ◽  
Vol 54 (1) ◽  
pp. 83-89
Author(s):  
Dj. Culafic ◽  
P. Miljic ◽  
M. Perisic ◽  
S. Djuranovic ◽  
D. Popovic ◽  
...  

Thrombosis of portal and hepatic veins is one of the most severe complications and most important causes of death of patients with chronic myeloproliferative diseases. Based on results of the past studies, myeloproliferative diseases were the causes of hepatic veins thrombosis in 30% and portal vein thrombosis in 20% of patients. The study presented 4 patients with myeloproliferative diseases complicated by thrombosis of splanchnic veins, aiming at the illustration of issue complexity in diagnostics and therapy. Two patients with portal vein thrombosis and recurring hemorrhage from esophageal varicosity were described. The first case was planned for shunting, while another case sustained bleeding on what account his anticoagulant therapy was discontinued, but it caused mesenterial thrombosis resulting in lethal outcome. Another two patients had hepatic veins thrombosis. Due to frequent, life-threatening bleeding from the esophageal and gastric varices, a patient with chronic Budd-Chiari syndrome and lineal vein thrombosis underwent mesocaval shunting. An immediate postoperative period was manifested by multiple thrombosis and hemorrhages that ended in his death. A patient with the acute Budd-Chiari syndrome was administered myelosuppressants and anticoagulants on time so reperfusion was restored. In myeloproliferative diseases, thrombosis of portal and hepatic veins gives rise to excessive portal hypertension with profuse hemorrhage from the esophageal and gastric varicosity which is difficult to manage because of complex coagulation disorders.

2004 ◽  
Vol 121 (6) ◽  
pp. 844-847 ◽  
Author(s):  
Maitreyee Bhattacharyya ◽  
Govind Makharia ◽  
M. Kannan ◽  
R.P.H. Ahmed ◽  
P.K. Gupta ◽  
...  

2009 ◽  
Vol 13 (1) ◽  
pp. 127-144 ◽  
Author(s):  
Paulo Lisboa Bittencourt ◽  
Cláudia Alves Couto ◽  
Daniel Dias Ribeiro

2004 ◽  
Vol 124 (3) ◽  
pp. 329-335 ◽  
Author(s):  
Alberto Alvarez-Larrán ◽  
Juan Carlos García-Pagán ◽  
Juan G. Abraldes ◽  
Eduardo Arellano ◽  
Juan Carlos Reverter ◽  
...  

2004 ◽  
Vol 78 (1) ◽  
pp. 333-334 ◽  
Author(s):  
George K Anagnostopoulos ◽  
George Margantinis ◽  
Panagiotis Kostopoulos ◽  
Glyceria Papadopoulou ◽  
Athanassios Roulias ◽  
...  

2016 ◽  
Vol 111 ◽  
pp. S815-S816
Author(s):  
Yezaz A. Ghouri ◽  
Akhil V. Shenoy ◽  
Heather L. Stevenson ◽  
Shehzad Merwat

Blood ◽  
2012 ◽  
Vol 120 (25) ◽  
pp. 4921-4928 ◽  
Author(s):  
Jasper H. Smalberg ◽  
Lidia R. Arends ◽  
Dominique C. Valla ◽  
Jean-Jacques Kiladjian ◽  
Harry L. A. Janssen ◽  
...  

Abstract Myeloproliferative neoplasms (MPNs) are the most common cause of Budd-Chiari syndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT). In this meta-analysis, we determined the prevalence of MPNs and their subtypes as well as JAK2V617F and its diagnostic role in these uncommon disorders. MEDLINE and EMBASE databases were searched. Prevalence of MPNs, JAK2V617F, and MPN subtypes were calculated using a random-effects model. A total of 1062 BCS and 855 PVT patients were included. In BCS, mean prevalence of MPNs and JAK2V617F was 40.9% (95% CI, 32.9%-49.5%) and 41.1% (95% CI, 32.3%-50.6%), respectively. In PVT, mean prevalence of MPNs and JAK2V617F was 31.5% (95% CI, 25.1%-38.8%) and 27.7% (95% CI, 20.8%-35.8%), respectively. JAK2V617F and MPNs were more frequent in BCS compared with PVT (P = .03 and P = .09, respectively). Polycythemia vera was more prevalent in BCS than in PVT (P = .001). JAK2V617F screening in splanchnic vein thrombosis (SVT) patients without typical hematologic MPN features identified MPN in 17.1% and 15.4% of screened BCS and PVT patients, respectively. These results demonstrate a high prevalence of MPNs and JAK2V617F in SVT patients and show differences in underlying etiology between these disorders. Furthermore, these results validate routine inclusion of JAK2V617F in the diagnostic workup of SVT patients.


2014 ◽  
Vol 33 (5) ◽  
pp. 489-491 ◽  
Author(s):  
Mohammed Amin Sakr ◽  
Nadia Abdelkader ◽  
Hany Dabbous ◽  
Ahmed Eldorry

Sign in / Sign up

Export Citation Format

Share Document